Esophageal, Gastric & Duodenal Disorders

Members interested in participating in the activities of the AGA Institute Council Esophageal, Gastric and Duodenal Disorders Section should contact us at agacouncil@gastro.org. We are especially interested in increasing participation of junior investigators, clinicians and international members.

 

MISSION STATEMENT AND FOCI

The EGD section continues to heavily contribute to the educational and research mission of the AGA Institute and remains a highly visible section at DDW®.  It is  the second largest section in the AGA Council. The attendance at Digestive Disease Week® (DDW) continues to be robust, with nearly all of the EGD section’s clinical sessions exceeding expected capacity. The section is diverse in regards to representation of multiple upper GI diseases including esophagus, stomach, and duodenum.  Advances continue to develop in the area of esophageal reflux and motility testing (e.g., high resolution manometry and mucosal impedance measurements), endoscopic reflux therapies as well as continued strong interest in both clinical and basic research in Eosinophilic esophagitis and Barrett's esophagus. Dominant areas of investigation in this section include esophageal physiologic testing, eosinophilic esophagitis, H. pylori infection and its chronic implications, GERD and extraesophageal GERD, Barrett's esophagus, esophageal and gastric dysmotility, and GI bleeding.

Over the last few years, the EGD section intensified their efforts at reducing overlap by consolidating some of  descriptors and proactively ensuring reduced programming redundancies.  The section continues to work with other council sections in cross-sectional opportunities. Section leaders believe the EGD section will continue to play a pivotal role in providing excellence in research and education, and strive to meet these goals by thoughtful programming of clinical and research fora in line with the demand of section members.

Areas of Focus:

  • GERD.
  • Esophageal motility disorders.
  • EoE.
  • H. pylori.
  • NSAIDS induced gastroduodenal ulcer diseases.

Council Leadership

John Kao, MD, AGAF
University of Michigan
Chair
Ikuo Hirano, MD, AGAF
Northwestern University School of Medicine
Vice chair